Loading...
XNAS
UPC
Market cap3mUSD
Jul 09, Last price  
5.35USD
1D
-7.84%
1Q
74.67%
IPO
-99.96%
Name

Universe Pharmaceuticals Inc

Chart & Performance

D1W1MN
XNAS:UPC chart
P/E
P/S
0.19
EPS
Div Yield, %
Shrs. gr., 5y
-9.82%
Rev. gr., 5y
-10.27%
Revenues
18m
-22.44%
28,514,18033,229,31630,703,96047,982,03140,143,15132,308,73523,024,45817,858,732
Net income
-4m
L-57.92%
7,602,9337,551,4657,558,22211,319,952-8,736,566-6,163,061-8,727,298-3,672,055
CFO
-5m
L-46.86%
4,455,59913,203,7556,115,157-2,055,847-1,312,3461,120,082-9,506,683-5,052,319

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Universe Pharmaceuticals Inc. (UPC) operates as a pharmaceutical enterprise primarily focused on the Chinese market. The company specializes in the production, promotion, and sale of products derived from traditional Chinese medicine (TCM). These remedies are designed to address common chronic health issues prevalent among the elderly, promoting physical well-being and longevity, in addition to offering medications for cold and flu symptoms. Beyond its own manufactured goods, UPC also functions as a distributor and vendor for a diverse range of third-party products. This extensive portfolio includes biomedical drugs, medical instruments, traditional Chinese medicine 'pieces' (raw ingredients), and various dietary supplements. Its clientele spans across the healthcare sector, encompassing other pharmaceutical companies, hospitals, clinics, and major drugstore chains. Established in 2019, the company's operations are headquartered in Ji'An, China, and it functions as a subsidiary of Sununion Holding Group Limited.
IPO date
Mar 23, 2021
Employees
224
Domiciled in
CN
Incorporated in
KY

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFY
2025‑092024‑092023‑092022‑092021‑092020‑092019‑092018‑09
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT